InMed Pharmaceuticals (INM) Change in Receivables (2019 - 2025)
InMed Pharmaceuticals (INM) reported Change in Receivables of -$159977.0 for Q4 2025, down 606.46% on a YoY basis from $31587.5 in Q4 2024, and down 30.96% quarter-over-quarter from -$122160.0 in Q3 2025.
InMed Pharmaceuticals (INM) Change in Receivables (2019 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported Change in Receivables for 7 years, with the latest figure at -$159977.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables fell 606.46% year-over-year to -$159977.0; the trailing twelve-month figure through Dec 2025 stood at -$77178.0 (up 30.03% YoY), and the FY2025 full-year result was $114690.0, up 24.07% from the prior year.
- Change in Receivables for Q4 2025 stood at -$159977.0, down from -$122160.0 in the prior quarter.
- The five-year high for Change in Receivables was $207019.0 in Q4 2023, with the low at -$165188.0 in Q1 2024.
- Historically, Change in Receivables has averaged $2061.0 across 5 years, with a median of $1142.5 in 2021.
- The largest YoY upside for Change in Receivables was 14451.57% in 2022 against a maximum downside of 2592.58% in 2022.
- InMed Pharmaceuticals' Change in Receivables stood at -$638.0 in 2021, then soared by 14451.57% to $91563.0 in 2022, then jumped by 126.09% to $207019.0 in 2023, then slumped by 110.94% to -$22645.0 in 2024, then tumbled by 606.46% to -$159977.0 in 2025.
- The last three Change in Receivables figures came in at -$159977.0 (Q4 2025), -$122160.0 (Q3 2025), and $99715.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -78.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 106.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -38.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 81.40 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 23.22 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 2.23 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 116.25 Mn |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -159,977.00 |
| Dec 31, 2025 | -159,977.00 |
| Sep 30, 2025 | -122,160.00 |
| Sep 30, 2025 | -122,160.00 |
| Jun 30, 2025 | 99,715.00 |
| Jun 30, 2025 | 99,715.00 |
| Mar 31, 2025 | 105,244.00 |
| Mar 31, 2025 | 105,244.00 |
| Dec 31, 2024 | -22,645.00 |
| Dec 31, 2024 | -22,645.00 |
| Sep 30, 2024 | -67,624.00 |
| Sep 30, 2024 | -67,624.00 |
| Jun 30, 2024 | 145,157.00 |
| Jun 30, 2024 | 145,157.00 |
| Mar 31, 2024 | -165,188.00 |
| Mar 31, 2024 | -165,188.00 |
| Dec 31, 2023 | 207,019.00 |
| Dec 31, 2023 | 207,019.00 |
| Sep 30, 2023 | -94,549.00 |
| Sep 30, 2023 | -94,549.00 |